lupin_pharma_logo

Lupin completes acquisition of US-based Gavis Pharmaceuticals

pharmafile | March 10, 2016 | News story | Research and Development, Sales and Marketing FDA, Gavis, Lupin, acquisition, generics 

Indian drug manufacturer Lupin has announced the completion of its acquisition of New Jersey-based pharmaceutical firm, Gavis, in a deal worth $880 million.

As reported previously, the deal will see Lupin enhance its presence in the US generic market, with access to Gavis’ 62 generic drugs, which the firm has already filed to the FDA for approval.

72% of these ANDA filings pending approval requests represent niche dosage forms with 18 Para IVs and eight FTFs products. The existing pending approvals of Gavis address a market of over $9 billion.

Advertisement

Vinita Gupta, chief executive officer at Lupin, comments: “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as speciality pipeline.”

Sean Murray

Related Content

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide

Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group in a …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

The Gateway to Local Adoption Series

Latest content